ProCE Banner Activity

New Developments in Chemotherapy-Based Treatment for Breast Cancer: Insights From SABCS 2019

Clinical Thought
Get insights from Sara Tolaney, MD, MPH, on key studies using chemotherapy-based regimens for HER2-negative and triple-negative breast cancer presented at the 2019 Breast Cancer meeting in San Antonio.

Released: January 27, 2020

Expiration: January 25, 2021

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Lilly, Merck, Nanostring, Nektar, Novartis, and Pfizer; has received consulting fees from AstraZeneca, Eisai, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer, and Tesaro; and has served on advisory boards for AstraZeneca, Celldex, Eisai, Genentech/Roche, Immunomedics, Lilly, Nanostring, Novartis, Merck, Puma, and Sanofi.

Additional Information

Program Medium

This program has been made available online.